BIO89-100
Treatment for Liver & Metabolic Disorders
Screenshots
 View Image |  View Image |
|---|---|
Hunter's comment
A novel long-acting glycopegylated fibroblast growth factor 21 analogue; the BIO89-100 Treatment for Liver & Metabolic Disorders could become a therapy for NASH (nonalcoholic steatohepatitis) given its ability to address the key liver pathologies (steatosis & fibrosis) & underlying metabolic dysregulation in NASH patients.
Link
This is posted on Steemhunt - A place where you can dig products and earn STEEM.
View on Steemhunt.com